Research map: Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer

Back to the article

Papers in this map

  1. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group · Howard I. Scher · 2008 · 2265 citations · Cited by this paper
  2. Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Riddhi A. Babel · 2026 · Related
  3. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials · Heiner C. Bucher · 1997 · 2086 citations · Cited by this paper
  4. Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · 2026 · Related
  5. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer · Ian D. Davis · 2019 · 1651 citations · Cited by this paper
  6. Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · 2026 · Related
  7. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer · Kim N. Chi · 2019 · 1577 citations · Cited by this paper
  8. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · 2026 · Related
  9. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer · Andrew J. Armstrong · 2019 · 1241 citations · Cited by this paper
  10. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · 2026 · Related
  11. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial · Karim S. Fizazi · 2019 · 841 citations · Cited by this paper
  12. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · 2026 · Related
  13. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study · Kim N. Chi · 2021 · 530 citations · Cited by this paper
  14. Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · 2026 · Related
  15. Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research · James Signorovitch · 2012 · 523 citations · Cited by this paper
  16. Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · 2026 · Related
  17. Correcting for non-compliance in randomized trials using rank preserving structural failure time models · James M. Robins · 1991 · 433 citations · Cited by this paper
  18. A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · 2026 · Related
  19. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal · David Phillippo · 2017 · 413 citations · Cited by this paper
  20. Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine · 2026 · Related
  21. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial · N.W. Clarke · 2019 · 405 citations · Cited by this paper
  22. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) · William Thomas Lowrance · 2023 · 320 citations · Cited by this paper
  23. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer · Andrew J. Armstrong · 2022 · 314 citations · Cited by this paper
  24. Performance Status in Patients With Cancer · Howard West · 2015 · 272 citations · Cited by this paper
  25. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) · Edoardo Francini · 2018 · 206 citations · Cited by this paper
  26. Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance · Rongbin Ge · 2022 · 193 citations · Cited by this paper
  27. Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence · Paramita Dasgupta · 2019 · 119 citations · Cited by this paper
  28. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials · Claire Louise Vale · 2023 · 95 citations · Cited by this paper
  29. ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials · Nathalie Grafféo · 2019 · 78 citations · Cited by this paper
  30. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison · Peter T. Nash · 2018 · 50 citations · Cited by this paper
  31. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses · Andrew J. Armstrong · 2020 · 42 citations · Cited by this paper
  32. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer · Susan Halabi · 2024 · 35 citations · Cited by this paper
  33. Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer · Roberto Iacovelli · 2018 · 30 citations · Cited by this paper
  34. Survival in Patients With De Novo Metastatic Prostate Cancer · Martin W. Schoen · 2024 · 26 citations · Cited by this paper
  35. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors · Kotaro Suzuki · 2024 · 24 citations · Cited by this paper
  36. Two-stage matching-adjusted indirect comparison · Remiro-Az\'ocar, Antonio · 2022 · 23 citations · Cited by this paper
  37. The impact of race on survival in metastatic prostate cancer: a systematic literature review · Stephen J. Freedland · 2023 · 22 citations · Cited by this paper
  38. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer · Simon Chowdhury · 2019 · 20 citations · Cited by this paper
  39. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy · Luigi Nocera · 2021 · 17 citations · Cited by this paper

Source: OpenAlex (CC0)